MedTrace Logo

64Cu-SAR-bisPSMA Positron Emission Tomography of Patients With Known or Suspected Prostate Cancer

NCT05286840 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2022-03-18

No results posted yet for this study

Summary

This research project is testing a new compound which may potentially detect specific cancer lesions in men with prostate cancer.

Conditions

Interventions

DIAGNOSTIC_TEST

64Cu-SAR-bisPSMA

Diagnostic PET/CT imaging agent targeted for Prostate Specific Membrane Antigen (PSMA)

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-28
Primary Completion
2023-03-28
Completion
2023-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05286840 on ClinicalTrials.gov